Melanoma, Version 4.2014

Restricted access

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

Provided content development and/or authorship assistance.

  • 1.

    SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:929.

  • 2.

    JemalASaraiyaMPatelP. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol2011;65(Suppl 1):S17-25.e11-13.

    • Search Google Scholar
    • Export Citation
  • 3.

    CurtinJABusamKPinkelDBastianBC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol2006;24:43404346.

  • 4.

    AgrawalSKaneJMIIIGuadagnoloBA. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer2009;115:58365844.

    • Search Google Scholar
    • Export Citation
  • 5.

    BurmeisterBHHendersonMAAinslieJ. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol2012;13:589597.

    • Search Google Scholar
    • Export Citation
  • 6.

    HendersonMABurmeisterBAinslieJ. Adjuvant radiotherapy after lymphadenectomy in melanoma patients: final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01) [abstract]. J Clin Oncol2013;31(Suppl 15):Abstract 9001.

    • Search Google Scholar
    • Export Citation
  • 7.

    BeadleBMGuadagnoloBABalloMT. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys2009;73:13761382.

    • Search Google Scholar
    • Export Citation
  • 8.

    ChangDTAmdurRJMorrisCGMendenhallWM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys2006;66:10511055.

    • Search Google Scholar
    • Export Citation
  • 9.

    SauseWTCooperJSRushS. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys1991;20:429432.

    • Search Google Scholar
    • Export Citation
  • 10.

    ConillCJorcanoSDomingo-DomenechJ. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res2007;17:304309.

    • Search Google Scholar
    • Export Citation
  • 11.

    HofmannMKieckerFWurmR. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol2006;76:5964.

    • Search Google Scholar
    • Export Citation
  • 12.

    MargolinKAtkinsBThompsonA. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol2002;128:214218.

    • Search Google Scholar
    • Export Citation
  • 13.

    LongGVMenziesAMNagrialAM. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol2011;29:12391246.

    • Search Google Scholar
    • Export Citation
  • 14.

    HauschildAGrobJJDemidovLV. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract]. J Clin Oncol2012;30(Suppl 18):Abstract LBA8500.

    • Search Google Scholar
    • Export Citation
  • 15.

    LongGVTrefzerUDaviesMA. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol2012;13:10871095.

    • Search Google Scholar
    • Export Citation
  • 16.

    FlahertyKTRobertCHerseyP. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med2012;367:107114.

  • 17.

    KimKBKeffordRPavlickAC. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol2013;31:482489.

    • Search Google Scholar
    • Export Citation
  • 18.

    ChapmanPBHauschildARobertC. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med2011;364:25072516.

  • 19.

    HauschildAGrobJJDemidovLV. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet2012;380:358365.

    • Search Google Scholar
    • Export Citation
  • 20.

    SosmanJAKimKBSchuchterL. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med2012;366:707714.

  • 21.

    SuFVirosAMilagreC. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med2012;366:207215.

    • Search Google Scholar
    • Export Citation
  • 22.

    FlahertyKTInfanteJRDaudA. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med2012;367:16941703.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 230 125 32
PDF Downloads 35 31 3
EPUB Downloads 0 0 0